Eli Lilly (LLY)

Innovent and Eli Lilly sign a China commercialization deal for Verzenios, expanding patient access while Lilly retains manufacturing.

Eli Lilly (NYSE:LLY) has outperformed the market over the past 20 years by 7.2% on an annualized basis producing an average annual return of 16.46%. Currently, Eli Lilly has a market capitalization of $1.06 trillion.

As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Phibro Animal Hea...

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Zoetis (NYSE:ZTS) and its pee...

What Happened? Shares of genomics company Illumina (NASDAQ:ILMN) fell 1.9% in the afternoon session after Swiss drugmaker Roche launched a next-generation ge...

FDA names seven companies to its PreCheck pilot to speed U.S. drug manufacturing reviews after receiving more than 80 applications.

All three ETFs complement each other well in a portfolio.

Among Nvidia, Apple, Alphabet, Microsoft, Amazon, Taiwan Semi, SpaceX, Broadcom, Tesla, Meta, Micron, Eli Lilly, and Berkshire Hathaway, there are a handful of bargains and pretenders.

SpaceX recently completed a record IPO.

The weight loss tailwind isn't about to come to a halt.

Pharmaceutical companies are on an M&A spree that could break records this year as they look for novel drug and clinical-stage candidates to bolster the development pipeline.

As AI stocks face volatility, capital is rotating into biotech, industrials, utilities, consumer staples, and dividend ETFs showing relative strength.

Why settle for puny yields when you can buy these monster dividend stocks?

These stocks are no-brainer buys.

These stocks are better bets to skyrocket than the much-hyped rocket stock.

Pfizer is deeply out of favor on Wall Street, which could be a huge opportunity for long-term dividend investors.

The top stocks are showing relative strength. Two are defensive growth plays.

There are still great opportunities in an otherwise volatile market.

Eli Lilly holds a dominant market share in the weight loss treatment category.

The pharma titan is expanding into new markets.

Eli Lilly is a leader in the revolutionary GLP weight-loss market. Lilly was one of 28 stocks new to best stock lists Friday.

Novo Nordisk offers dividend income and MASH upside versus Lilly's high‑growth obesity lead.

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 6.3% in the afternoon session after the European Medicines Agency's commit...

The smartphone could be a thing of the past if Snap has its way. But at $2,195, it could be a tall order to sell Specs to consumers, even if they were stylish.